SciELO - Scientific Electronic Library Online

 
vol.20 issue2Plan for the Rehabilitation of the Upper Airway and Deglutition Function in Patients with a Tracheostomy CannulaPulmonary Involvement with Cryptococcus Laurentii in an Immunocompromised Patient author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Journal

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • Have no similar articlesSimilars in SciELO

Share


Revista americana de medicina respiratoria

On-line version ISSN 1852-236X

Abstract

Pleuropulmonary Fibrosis Associated with the Chronic Intake of Ergotamine. Rev. am. med. respir. [online]. 2020, vol.20, n.2, pp.181-184. ISSN 1852-236X.

Ergotamine is used as a treatment of various diseases. Its chronic use may cause pleuropulmonary, retroperitoneal or pericardial fibrosis. Although pleuropulmonary fibrosis is an uncommon adverse effect, it may be serious and irreversible, thus the early suspension of the drug is the specific treatment. We report three cases of pleuropulmonary fibrosis associated with the chronic intake of ergotamine. In all the cases, the prolonged time of use of this drug and the lack of exposure to other possible drugs or agents acceptable to generate this pleuropulmonary alteration were the main diagnostic indicators, since there aren’t any specific supplementary studies.

Keywords : Ergotamine; Ergotamine/Adverse effects; Pulmonary fibrosis.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )

 

Creative Commons License All the contents of this journal, except where otherwise noted, is licensed under a Creative Commons Attribution License